Grifols (GRFS) Operating Leases (2019 - 2025)
Grifols' (GRFS) quarterly Operating Leases came in at $1.1 billion in Q4 2025, up 2.98% YoY from $1.1 billion in Q4 2024, and up 2.98% on a QoQ basis from $1.1 billion in Q4 2024.
Grifols (GRFS) Operating Leases (2019 - 2025) Analysis & Trends
Grifols (GRFS) has 7 years of Operating Leases data on file, last reported at $1.1 billion in Q4 2025.
- Quarterly Operating Leases rose 2.98% year-over-year to $1.1 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 billion (up 2.98% YoY) and the FY2025 annual result came in at $1.1 billion, up 2.98% from the prior year.
- Operating Leases climbed to $1.1 billion in Q4 2025, from $1.1 billion in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $1.1 billion in Q4 2025 to a low of $933.1 million in Q4 2022.
- A 5-year average of $1.0 billion and a median of $1.1 billion in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases declined 1.15% — and 2023, when it gained 15.79%.
- Tracing GRFS's Operating Leases over 5 years: stood at $944.0 million in 2021, then dropped by 1.15% to $933.1 million in 2022, then climbed by 15.79% to $1.1 billion in 2023, then advanced by 1.37% to $1.1 billion in 2024, then rose by 2.98% to $1.1 billion in 2025.
- The last three Operating Leases figures came in at $1.1 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.1 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn |
| 2 | AbbVie | 470.28 Bn | 463.71 Bn | 12.70 Bn |
| 3 | Merck | 378.50 Bn | 371.36 Bn | 12.21 Bn |
| 4 | Novartis Ag | 302.91 Bn | 295.22 Bn | 11.24 Bn |
| 5 | Astrazeneca | 259.04 Bn | 254.14 Bn | 12.86 Bn |
| 6 | Amgen | 237.16 Bn | 223.17 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.02 Bn | 179.84 Bn | 6.22 Bn |
| 8 | Pfizer | 160.85 Bn | 149.16 Bn | 10.94 Bn |
| 9 | Gsk | 105.85 Bn | 101.69 Bn | 8.24 Bn |
| 10 | Grifols | 5.47 Bn | 4.47 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.13 Bn |
| Dec 31, 2024 | 1.10 Bn |
| Dec 31, 2023 | 1.08 Bn |
| Dec 31, 2022 | 933.11 Mn |
| Dec 31, 2021 | 943.96 Mn |
| Dec 31, 2020 | 823.70 Mn |
| Dec 31, 2019 | 770.71 Mn |